Antiplatelet and direct oral anticoagulation management after coronary artery bypass graft surgery: the Cinderella of current cardiovascular trials, please show me (some) evidence-Reference-Cited by-同舟云学术

Antiplatelet and direct oral anticoagulation management after coronary artery bypass graft surgery: the Cinderella of current cardiovascular trials, please show me (some) evidence

Published:2021-02-22 Issue:22 Volume:42 Page:2145-2148
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Schoenrath Felix¹²^ORCID,Just Isabell Anna¹²,Falk Volkmar¹³⁴^ORCID,Emmert Maximilian Y¹³⁵^ORCID

Affiliation:

1. Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany

2. DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany

3. Department of Cardiothoracic Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany

4. Department of Health Sciences, Translational Cardiovascular Technologies, ETH Zurich, Zurich, Switzerland

5. Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/42/22/2145/38501429/ehab033.pdf

Reference10 articles.

1. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Throacic Surgery (EACTS;Valgimigli;Eur Heart J,2018

2. 2017 EACTS guidelines on perioperative medication in adult cardiac surgery;Sousa-Uva;Eur J Cardiothorac Surg,2018

3. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes;Knuuti;Eur Heart J,2020

4. Integrating platelet and coagulation activation in fibrin clot formation;Swieringa;Res Pract Thromb Haemost,2018

5. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome—thrombolysis in myocardial infarction 51 (ATLAS-ACS2 TMI51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome;Gibson;Am Heart J,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polyester urethane urea (PEUU) functionalization for enhanced anti-thrombotic performance: advancing regenerative cardiovascular devices through innovative surface modifications;Frontiers in Bioengineering and Biotechnology;2023-09-20

2. Chinese expert consensus on antithrombotic management of high‐risk elderly patients with chronic coronary syndrome;AGING MEDICINE;2023-02-05

3. A comprehensive update on cardiovascular surgery: challenges and opportunities;European Heart Journal;2021-12-28